Mealogic, the ready-to-eat B2B2C meal delivery platform, announced that it has secured $16 million in funding to support the company’s growth.
The capital will enable Mealogic to enhance its customer experience, scale business development, and expand access to personalized nutrition solutions that support the prevention and reversal of diet-related disease.
Participants include S2G Investments, a multi-stage firm with a dedicated food and agriculture strategy; Dohmen Company Foundation, whose vision is life without diet-related disease; U.S. Venture Partners; and Unilever Ventures.
“Mealogic is designed to be the engine behind today’s leading food-as-medicine companies,” said Derek Mansfield, CEO of Mealogic, in a statement. “Our platform allows partners to deliver high-quality meals that reflect their unique dietary programs, whether they’re focused on metabolic health, complementing GLP-1 protocols, or other nutrition-focused plans. We handle everything from e-commerce to food production to delivery, which frees up partners to focus on growth, innovation, and the communities they serve.”
Unlike direct-to-consumer meal services, Mealogic operates as a white-label platform, enabling health-care providers, wellness brands, and clinical programs to deliver curated meals that meet specific nutritional standards — such as low sodium, plant-based, or anti-inflammatory — under their own brand.
Using a catalog of more than 5,000 nutritionally profiled meals, Mealogic’s system filters options based on each partner’s dietary requirements and handles menu development, payment processing, production, delivery, and customer service.
Each week, the company offers more than 200 unique science-backed dishes designed to support positive health outcomes.
